Revolo Biotherapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Stevenage United Kingdom (2011)

Organization Overview

First Clinical Trial
2017
NCT03058458
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Chief Medical Officer, Revolo Biotherapeutics | Immune Regulation | Revolo Biotherapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

irl201104 (4 trials)

Drugs in Phase 1 Trials (1)

pin201104 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2